Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer.

ABSTRACT:

Background

Gut bacteria-derived short-chain fatty acids (SCFA) and branched-chain fatty acids (BCFA) are considered to have beneficial metabolic, anti-inflammatory as well as anti-carcinogenic effects. Previous preclinical studies indicated bidirectional interactions between gut bacteria and the chemotherapeutic capecitabine or its metabolite 5-FU. This study investigated the effect of three cycles of capecitabine on fecal SCFA and BCFA levels and their associations with tumor response, nutritional status, physical performance, chemotherapy-induced toxicity, systemic inflammation and bacterial abundances in patients with colorectal cancer (CRC).

Methods

Forty-four patients with metastatic or unresectable CRC, scheduled for treatment with capecitabine (± bevacizumab), were pr

SUBMITTER: Ziemons J 

PROVIDER: S-EPMC10618330 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature